Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.
Emerg Microbes Infect. 2020 Dec; 9(1):2091-2093.EM

Abstract

We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.

Authors+Show Affiliations

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Department of Microbiology, Harvard Medical School, Boston, MA, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.W. M. Keck Structural Biology Laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.W. M. Keck Structural Biology Laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Department of Microbiology, Harvard Medical School, Boston, MA, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Pub Type(s)

Letter

Language

eng

PubMed ID

32930052

Citation

Wang, Pengfei, et al. "SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients With Severe Disease." Emerging Microbes & Infections, vol. 9, no. 1, 2020, pp. 2091-2093.
Wang P, Liu L, Nair MS, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9(1):2091-2093.
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., Garg, A., Purpura, L. J., Laracy, J. C., Yu, J., Joshua-Tor, L., Sodroski, J., Huang, Y., & Ho, D. D. (2020). SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerging Microbes & Infections, 9(1), 2091-2093. https://doi.org/10.1080/22221751.2020.1823890
Wang P, et al. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients With Severe Disease. Emerg Microbes Infect. 2020;9(1):2091-2093. PubMed PMID: 32930052.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. AU - Wang,Pengfei, AU - Liu,Lihong, AU - Nair,Manoj S, AU - Yin,Michael T, AU - Luo,Yang, AU - Wang,Qian, AU - Yuan,Ting, AU - Mori,Kanako, AU - Solis,Axel Guzman, AU - Yamashita,Masahiro, AU - Garg,Ankur, AU - Purpura,Lawrence J, AU - Laracy,Justin C, AU - Yu,Jian, AU - Joshua-Tor,Leemor, AU - Sodroski,Joseph, AU - Huang,Yaoxing, AU - Ho,David D, PY - 2020/9/16/pubmed PY - 2020/10/6/medline PY - 2020/9/15/entrez KW - SARS-CoV-2 KW - antibody KW - neutralization KW - non-severe KW - severe SP - 2091 EP - 2093 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 9 IS - 1 N2 - We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/32930052/SARS_CoV_2_neutralizing_antibody_responses_are_more_robust_in_patients_with_severe_disease_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1823890 DB - PRIME DP - Unbound Medicine ER -